Key result
Being treated in Europe versus the United States was not associated with a significant difference in 2-year major cardiovascular events risk after PCI.
Why the study?
Data on geographical variations in DAPT cessation and their impact on outcomes after PCI were limited.
Does geographic location (United States vs. Europe) affect DAPT cessation patterns and 2-year MACE in patients undergoing PCI with stent implantation?
Cohort (n=5,018)
Yes
Does geographic location (United States vs. Europe) affect DAPT cessation patterns and 2-year MACE in patients undergoing PCI with stent implantation?
Answers are grounded in this paper and cite their sources.
Despite significant geographical variations in DAPT cessation patterns between the U.S. and Europe, the associated cardiovascular risk of cessation remains uniform and overall 2-year MACE rates are similar.
Background Data on geographical variations in dual antiplatelet therapy (DAPT) cessation and the impact on outcomes after percutaneous coronary intervention (PCI) are limited. We sought to evaluate geographical patterns of DAPT cessation and associated outcomes in patients undergoing PCI in the United States versus Europe. Methods Analyzing data from the PARIS registry, we studied 3,660 U.S. patients (72.9%) and 1,358 European patients (27.1%) that underwent PCI with stent implantation. DAPT cessation was classified as physician-recommended discontinuation, interruption (< 14 days), or disruption due to bleeding or noncompliance. The primary endpoint was 2-year major adverse cardiovascular events (MACE) defined as a composite of cardiac death, stent thrombosis, myocardial infarction, or target lesion revascularization. Results Cardiovascular risk factors were more common in the United States, whereas procedural complexity was greater in Europe. The incidence of 2-year DAPT discontinuation was significantly lower in U.S. versus European patients (30.7% vs. 65.6%; p < 0.001); however, rates of interruption (13.7% vs. 1.5%, p < 0.001) and disruption (17.7% vs. 5.1%, p < 0.001) were higher. DAPT discontinuation was associated with lower adjusted risk, whereas DAPT disruption was associated with greater risk for 2-year MACE, without interaction by region. After adjustment for baseline characteristics and DAPT cessation, 2-year MACE risk was not statistically different between regions (10.3% for Europe vs. 11.9% for U.S., adjusted hazard ratio 0.81, 95% confidence interval 0.65–1.01, p = 0.065). Conclusion DAPT cessation patterns, along with clinical and angiographic risk, vary substantially between PCI patients in the U.S. versus Europe. Despite such differences, cardiovascular risk associated with DAPT cessation remains uniform.
No takes yet. Share an insight, caveat, or question.
Vogel et al. (2019) conducted a cohort in Patients undergoing percutaneous coronary intervention (PCI) with stent implantation (n=5,018). European region vs. United States region was evaluated on 2-year major adverse cardiovascular events (MACE) defined as a composite of cardiac death, stent thrombosis, myocardial infarction, or target lesion revascularization (adjusted HR 0.81, 95% CI 0.65-1.01, p=0.065). Being treated in Europe versus the United States was not associated with a significant difference in 2-year major cardiovascular events risk after PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: